Electrochemotherapy of skin metastases from malignant melanoma: a PRISMA-compliant systematic review.
Electrochemotherapy
Local control
Melanoma
Skin metastases
Systematic review
Journal
Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
19
11
2021
accepted:
01
07
2022
pubmed:
23
7
2022
medline:
17
9
2022
entrez:
22
7
2022
Statut:
ppublish
Résumé
The main treatment of MM metastases are systemic therapies, surgery, limb perfusion, and intralesional talimogene laherparepvec. Electrochemotherapy (ECT) is potentially useful also due to the high response rates recorded in cancers of any histology. No randomized studies comparing ECT with other local therapies have been published on this topic. We analyzed the available evidence on efficacy and toxicity of ECT in this setting. PubMed, Scopus, and Cochrane databases were screened for paper about ECT on MM skin metastases. Data about tumor response, mainly in terms of overall response rate (ORR), toxicity (both for ECT alone and in combination with systemic treatments), local control (LC), and overall survival (OS) were collected. The methodological quality was assessed using a 20-item validated quality appraisal tool for case series. Overall, 18 studies were included in our analysis. In studies reporting "per patient" tumor response the pooled complete response (CR) was 35.7% (95%CI 26.0-46.0%), and the pooled ORR was 80.6% (95%CI 68.7-90.1%). Regarding "per lesion" response, the pooled CR was 53.5% (95%CI 42.1-64.7%) and the pooled ORR was 77.0% (95%CI 56.0-92.6%). One-year LC rate was 80%, and 1-year OS was 67-86.2%. Pain (24.2-92.0%) and erythema (16.6-42.0%) were the most frequent toxicities. Two studies reported 29.2% and 41.6% incidence of necrosis. ECT is effective in terms of tumor response and tolerated in patients with skin metastases from MM, albeit with a wide variability of reported results. Therefore, prospective trials in this setting are warranted.
Identifiants
pubmed: 35869314
doi: 10.1007/s10585-022-10180-9
pii: 10.1007/s10585-022-10180-9
pmc: PMC9474499
doi:
Substances chimiques
Bleomycin
11056-06-7
Types de publication
Journal Article
Review
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
743-755Informations de copyright
© 2022. The Author(s).
Références
J Surg Oncol. 2014 Nov;110(6):770-5
pubmed: 24996052
Clin Exp Metastasis. 2021 Feb;38(1):1-10
pubmed: 33180222
Ann Surg Oncol. 2008 Aug;15(8):2215-22
pubmed: 18498012
J Clin Oncol. 2009 Dec 1;27(34):5763-71
pubmed: 19884534
Actas Dermosifiliogr. 2017 Mar;108(2):91-97
pubmed: 27769538
Eur J Cancer. 2020 Oct;138:30-40
pubmed: 32836172
J Am Coll Surg. 2019 Apr;228(4):644-649
pubmed: 30690076
Melanoma Res. 2009 Oct;19(5):321-6
pubmed: 19641475
Ann Oncol. 2013 Aug;24(8):2174-80
pubmed: 23666915
G Ital Dermatol Venereol. 2016 Oct;151(5):499-506
pubmed: 27595201
Mol Clin Oncol. 2021 Apr;14(4):64
pubmed: 33680455
Cancer Immunol Immunother. 2016 Aug;65(8):951-9
pubmed: 27294607
Cancer Immunol Res. 2016 Sep 2;4(9):744-54
pubmed: 27466265
Eur J Surg Oncol. 2019 Dec;45(12):2257-2267
pubmed: 31285093
Int J Dermatol. 2019 Aug;58(8):865-870
pubmed: 30479009
Bioelectrochemistry. 2018 Feb;119:161-171
pubmed: 29024870
Acta Oncol. 2018 Jul;57(7):874-882
pubmed: 29577784
Open Med. 2009;3(3):e123-30
pubmed: 21603045
Melanoma Manag. 2015 May;2(2):127-132
pubmed: 30190842
Melanoma Res. 2005 Feb;15(1):45-51
pubmed: 15714120
Actas Dermosifiliogr (Engl Ed). 2018 Jun;109(5):390-398
pubmed: 29650221
Actas Dermosifiliogr. 2015 May;106(4):285-91
pubmed: 25512237
Melanoma Res. 2000 Oct;10(5):468-74
pubmed: 11095408
Melanoma Res. 2000 Aug;10(4):381-5
pubmed: 10985673
Br J Surg. 2012 Jun;99(6):821-30
pubmed: 22508342
Cancer Immunol Immunother. 2008 Sep;57(9):1291-300
pubmed: 18259749
J Clin Oncol. 2015 Apr 1;33(10):1191-6
pubmed: 25713437
Br J Dermatol. 2017 Jun;176(6):1475-1485
pubmed: 28118487
Expert Rev Anticancer Ther. 2010 May;10(5):729-46
pubmed: 20470005
J Immunother Cancer. 2019 Jun 6;7(1):145
pubmed: 31171039
Arch Dermatol. 1996 Nov;132(11):1353-7
pubmed: 8915314
Acta Oncol. 2022 May;61(5):533-544
pubmed: 34889156
J Cutan Med Surg. 2006 May-Jun;10(3):115-21
pubmed: 17241586
Dermatol Surg. 2011 Jun;37(6):816-24
pubmed: 21605245
Radiol Oncol. 2016 Feb 16;50(1):21-7
pubmed: 27069446
Cancer Treat Res. 2016;167:209-29
pubmed: 26601864
Oncoimmunology. 2015 May 22;4(6):e1008842
pubmed: 26155423
Dermatol Ther. 2014 May-Jun;27(3):148-52
pubmed: 24903471
Clin Cancer Res. 2000 Mar;6(3):863-7
pubmed: 10741708
Cancers (Basel). 2021 Aug 25;13(17):
pubmed: 34503099